Endurance RP (HK:0575) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Endurance RP reported a loss of US$2.62 million for the first half of 2024, primarily due to operating and R&D expenses, while also facing a capital deficiency of US$4.07 million. The company is awaiting NDA submission for Senstend™ in China, which could lead to future payments from Wanbang Biopharmaceutical, and is also progressing with the Phase 3 clinical studies of Fortacin™ in the US. Amidst these developments, Endurance RP remains focused on commercializing its products in key markets and integrating its AI-driven Deep Longevity technology into its business model.
For further insights into HK:0575 stock, check out TipRanks’ Stock Analysis page.
